What side effects should I expect when starting GLP-1 medication
Sporadic reports of skeletal muscle decline highlight the need for careful monitoring, as sarcopenia, characterized by reduced muscle mass and impaired physical function, may worsen metabolic outcomes and increase morbidity [19, 20]
Eli Lilly, which makes Zepbound and Mounjaro, just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication
Exfoliating More Is Not Always the Answer When skin looks dull or crepey, it can be tempting to increase exfoliation
Monlunabant: A treatment for obesity Developed by Novo Nordisk, Monlunabant is not a GLP-1 receptor agonist at all, but a treatment for obesity